Zeke Capital Advisors LLC Sells 2,897 Shares of Acceleron Pharma Inc (NASDAQ:XLRN)

Zeke Capital Advisors LLC lowered its stake in shares of Acceleron Pharma Inc (NASDAQ:XLRN) by 16.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,796 shares of the biopharmaceutical company’s stock after selling 2,897 shares during the period. Zeke Capital Advisors LLC’s holdings in Acceleron Pharma were worth $608,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently added to or reduced their stakes in XLRN. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Acceleron Pharma by 13.7% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,958 shares of the biopharmaceutical company’s stock valued at $138,000 after purchasing an additional 356 shares in the last quarter. Citizens Financial Group Inc RI purchased a new position in shares of Acceleron Pharma in the first quarter valued at $47,000. Quadrant Capital Group LLC purchased a new position in shares of Acceleron Pharma in the first quarter valued at $46,000. Wealthstreet Investment Advisors LLC grew its holdings in shares of Acceleron Pharma by 6.9% in the first quarter. Wealthstreet Investment Advisors LLC now owns 20,250 shares of the biopharmaceutical company’s stock valued at $943,000 after purchasing an additional 1,300 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY grew its holdings in shares of Acceleron Pharma by 12.6% in the first quarter. Metropolitan Life Insurance Co NY now owns 13,963 shares of the biopharmaceutical company’s stock valued at $650,000 after purchasing an additional 1,563 shares in the last quarter. Hedge funds and other institutional investors own 92.52% of the company’s stock.

In other news, Director Jean George sold 25,688 shares of Acceleron Pharma stock in a transaction on Wednesday, June 26th. The stock was sold at an average price of $39.16, for a total transaction of $1,005,942.08. Following the completion of the sale, the director now directly owns 23,750 shares in the company, valued at $930,050. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Joseph S. Zakrzewski bought 5,000 shares of the firm’s stock in a transaction dated Friday, June 14th. The shares were acquired at an average price of $38.05 per share, with a total value of $190,250.00. Following the completion of the transaction, the director now owns 12,750 shares of the company’s stock, valued at approximately $485,137.50. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 63,726 shares of company stock valued at $2,519,969. Corporate insiders own 2.50% of the company’s stock.

XLRN has been the subject of a number of recent research reports. JPMorgan Chase & Co. cut their target price on shares of Acceleron Pharma from $61.00 to $58.00 and set an “overweight” rating for the company in a report on Tuesday. Barclays lowered shares of Acceleron Pharma from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $54.00 to $45.00 in a report on Friday, May 3rd. Goldman Sachs Group reissued a “neutral” rating and issued a $54.00 target price on shares of Acceleron Pharma in a report on Wednesday, May 29th. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $74.00 price objective (up from $71.00) on shares of Acceleron Pharma in a research note on Friday, May 10th. Finally, Zacks Investment Research reaffirmed a “hold” rating on shares of Acceleron Pharma in a research note on Saturday, July 20th. Six investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Acceleron Pharma currently has an average rating of “Buy” and a consensus price target of $60.33.

NASDAQ XLRN traded up $0.31 on Tuesday, hitting $41.80. 189,902 shares of the stock were exchanged, compared to its average volume of 278,499. The company has a quick ratio of 19.26, a current ratio of 19.26 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average price of $41.70. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of -16.14 and a beta of 1.18. Acceleron Pharma Inc has a 52-week low of $37.01 and a 52-week high of $59.59.

Acceleron Pharma (NASDAQ:XLRN) last released its earnings results on Monday, August 5th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.10). Acceleron Pharma had a negative return on equity of 35.94% and a negative net margin of 965.39%. The business had revenue of $27.67 million for the quarter, compared to the consensus estimate of $28.72 million. During the same quarter last year, the business posted ($0.63) earnings per share. The firm’s revenue for the quarter was up 649.9% compared to the same quarter last year. On average, research analysts forecast that Acceleron Pharma Inc will post -2.44 earnings per share for the current year.

Acceleron Pharma Company Profile

Acceleron Pharma Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which is in Phase III clinical trials for the treatment of myelodysplastic syndromes and beta-thalassemia; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia and myelofibrosis.

Featured Story: When is a capital gain realized?

Want to see what other hedge funds are holding XLRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Acceleron Pharma Inc (NASDAQ:XLRN).

Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)

Receive News & Ratings for Acceleron Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma and related companies with MarketBeat.com's FREE daily email newsletter.